The role of thiotepa in autologous bone marrow transplantation for acute leukemia

Leukemia Research

Volumn 22, Issue 11, 1998, Pages 991-995

  Nagler, Arnon ^a   Finlander, Rosales ^a   Or, Reuven ^a   Naparstek, Elizabeth ^a   Varadi, Gabor ^a   Slavin, Shimon ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

Acute leukemia; Autologous bone marrow transplantation; Busulfan; Cyclophosphamide; Thiotepa

Indexed keywords

ALKYLATING AGENT; BUSULFAN; CYCLOPHOSPHAMIDE; THIOTEPA;

ACUTE LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ACUTE MYELOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; CANCER CLASSIFICATION; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; FEMALE; FEVER; GASTROINTESTINAL TOXICITY; HUMAN; HUMAN CELL; LEUKEMIA REMISSION; LIVER TOXICITY; LUNG HEMORRHAGE; LUNG TOXICITY; MALE; MUCOSA INFLAMMATION; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; PRIORITY JOURNAL; RECURRENCE RISK; TOXICITY; VOMITING;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW TRANSPLANTATION; BUSULFAN; CHILD; CHILD, PRESCHOOL; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; EVALUATION STUDIES; FEMALE; HUMANS; INFANT; LEUKEMIA, LYMPHOCYTIC, ACUTE; LEUKEMIA, MYELOCYTIC, ACUTE; MALE; MIDDLE AGED; THIOTEPA; TIME FACTORS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS;

EID: 0031663789     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0145-2126(98)00102-7     Document Type: Article

References (37)

1. Varadi G, Nagler A. Conditioning regimen in autologous bone marrow transplantation. Clin Immunother. 2:1994;343.
2. Start RK. Autologous bone marrow transplantation for leukemia. Sem Oncol. 20:1993;40.
3. Groin NC, Aegerter P, Auvert B. Autologous bone marrow transplantation for acute leukemia in remission, an analysis of 1322 cases. Bone Marrow Transplant. 4:1989;3.
4. Thomas ED., Buckner CD., Banaji M, Clift RA, Goodel BW. One hundred patients with acute leukemia treated by chemotherapy, total body irradiation and allogeneic marrow transplantation. Blood. 49:1977;51.
5. Santos GW. The development of busulfan-cyclophosphamide preparative regimens. Sem Oncol. 20:1993;12.
6. Tutshka PJ, Copelan EA, Klein JP. Bone marrow transplantation for leukemia following a new busulfan-cyclophosphamide regimen. Blood. 70:1987;1382.
7. Santos GW, Tutshka PJ, Brookmeyer R, Saral R, Beschorner WE, Bias WB, Braine HG, Burns WH, Elfenbein GJ, Kaizer H. Bone marrow transplant for acute nonlymphocytic leukemia after treatment with busulfan-cyclophosphamide. New Engl J Med. 309:1983;1347.
8. Buckner CD, Demire T, Appelbaum FR, Lambert K, Bensinger WL, Clift R, Storb R, Slaterry JT. Busulfan-cyclophosphamide and total body irradiation for allogeneic marrow transplantation in advanced acute myelogenous leukemia: phase I dose escalation of busulfan based on targeted plasma levels. Bone Marrow Transplant. 17:1996;341.
9. Niederwieser D, Granema A, Herman J, Kolb HJ, Zwaun F, Gratwohl A. Poor response to induction chemotherapy is an indicator of poor survival after bone marrow transplantation for acute lymphoblastic leukemia. Bone Marrow Transplant. 4:1992;559.
10. Miller C, Wagne r JE, Vogelsang GB. A randomized trial of busulfan cyclophosphamide and total body irradiation as preparative regimen for patients with chronic myelogenous leukemia. Blood. 80:1992;291.
11. Storb R. Critical issues in bone marrow transplantation. Transplant Proc. 19:1987;2774.
12. Nag S, Waxman D. Thiotepa oxygenation by constitutive hepatic P450 enzyme and drug modulation of metabolism and clearance in vivo. Cancer Res. 51:1991;2340.
13. Kamni N, Augest CS, Bunin N, Leahey A, Bayever E, Goldwein J, Zusman J, Evans AE, Amigo GD. Thiotepa, etoposide and fractionated total body irradiation as a preparative regimen prior to bone marrow transplantation for poor prognosis patients with neuroblastoma. Bone Marrow Transplant. 17:1996;911.
14. Bitron JD, Samuel B, Klein L, Hanaver S, Johnson L, Martinez J, Harris E, Kempler S, White W. Tandem high dose chemotherapy supported by hematopoietic progenitor cells yields prolonged survival in stage IV breast cancer. Bone Marrow Transplant. 15:1996;157.
15. Emanuel NM, Konovalova NP, Djachkovfkaya RF Toxicity, antitumor activity and pharmacokinetics of labelled thiotepa analogs. Cancer Treat Rep. 60:1976;1605.
16. Odwyer PJ, Lacreat F, Engstrom PF, Peter R, Tartaglia L, Cole D, Litwin S, DeVita J, Poplack D, Delap RJ. Phase I pharmacokinetics and reevaluation of thiotepa. Cancer Res. 51:1991;3171.
17. Heideman RL, Cole D, Bales F. Phase I pharmacokinetic evaluation of thiotepa in the cerebrospinal fluid and plasma of pediatric patients, evidenced for dose dependent plasma clearance of thiotepa. Canc Res. 49:1989;736.
18. Wolf SN, Herzig RH, Fay JW. High dose of thiotepa with autologous bone marrow transplantation: Phase I studies. Sem Oncol. 17:1990;2.
19. Bearman SI, Appelbaum FR, Buckner CD. Regimen related toxicity in patients undergoing bone marrow transplantation. Clin Oncol. 6:1988;1562.
20. Barnard GA. Significance test for 2x2 tables. Biometrika. 34:1947;123.
21. Fisher R.A. Statistical Methods for Research Workers. 5th edn:1981;19-32 Oliver & Boyd, Edinburgh.
22. Kaplan E, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc. 53:1958;457.
23. Mantel N. Evaluation of survival data and two new rank order tatistics arising in its consideration. Cancer Chemother Rep. 50:1966;163.
24. Cox DR. Regression models and life tables. J R Stat Soc. 34:1972;187.
25. Sierra J, Granena A, Garcia J, Valls A, Carreras E, Rovira M, Canals C, Martinez E, Punti C, Algara M. Autologous bone marrow transplantation for acute leukemia: results and prognostic factors in 90 consecutive patients. Bone Marrow Transplant. 12:1993;157.
26. Niederwieser D, Granena A, Hernan J, Kolb HJ, Zwaan F, Gratwohl A. Poor response to induction chemotherapy is an indicator of poor survival after bone marrow transplantation for acute lymphoblastic leukemia. Bone Marrow Transplant. 9:1992;439.
27. Phillips GL, Shepherd JD, Barnett MJ, Soirelli J, Nevil TJ, Cha KW, Lansdorp PM, Klingeman HJ. Cyclophosphamide and melphalan conditioning for autologous bone marrow transplantation in hematologic malignancies. J Clin Oncol. 9:1991;1980.
28. Meletios A, Dimopoulos M, Alexanian R, Przepiorka D, Hester J, Andersson B, Giralt S, Mehra R, Reading C, Deisseroth A, Champlin R. Thiotepa, Busulfan and Cyclophosphamide: A new preparative regimen for autologous bone marrow or blood stem cell transplantation in high risk multiple myeloma. Blood. 82:1993;2324.
29. Przepiorka D, Dimopoulos M, Smith J, Ippoliti C, Dierer K, Luna M, Champlin R. Thiotepa, busulfan and cyclophosphamide as a new preparative regimen for marrow transplantation: risk factors for early regimen related toxicity. Ann Hematol. 68:1994;183.
30. Przepiorka D, Ippoliti C, Giralt S, Van Biesen K, Mehra R, Deisseroth A, Andersson B, Lina M, Cork A, Lee M, Estey E. A phase I-II study of high dose thiotepa, busulfan and cyclophosphamide as a preparative regimen for allogeneic bone marrow transplantation. Bone Marrow Transplant. 14:1994;449.
31. Przepiorka D, Madden T, Ippoliti C, Estrou Z, Dimopoulos M. Dosing of thiotepa for myeloablative therapy. Canc Chemotherap Pharmacol. 37:1995;155.
32. Shulman HM, Hinterberg W. Veno-occlusive disease, liver toxicity syndrome after autologous bone marrow transplantation. Bone Marrow Transplant. 10:1992;197.
33. Vanderwall E, Beijnen JH. High dose chemotherapy regimens for solid tumors. Canc Treat Rev. 21:1995;205.
34. Spitzer GR, Cottler FM, Torriso J. Escalating doses of etoposide with cyclophosphamide and fractionated total body irradiation or busulfan as conditioning for bone marrow transplantation. Bone Marrow Transplant. 4:1989;559.
35. Weaver CH, Besinger WI, Appelbaum K, Lilleby B, Sadmaier M, Rowley S, Petersdorf S, Rivkin T, Gooley P, Weiden N, Zuckerman P, Montgomery K, Trueblood J, Klarnet J, Buckner CD. Phase I study of high dose busulfan, melphalan and thiotepa with autologous stem cell support in patients with refractory malignancies. Bone Marrow Transplant. 2:1995;346.
36. Devine M, Geller B, Holland K, Wingard R, Saral R. New preparative regimens with diaziquone or cytarabine in combination with busulfan and cyclophosphamide. Sem Oncol. 20:1993;56.
37. Geller RB, Myers S, Devine S, Larson A, Williams F, Park CL, Topper RL. Phase I study of busulfan cyclophosphamide and timed sequential escalating doses of cytarabine followed by bone marrow transplantation. Bone Marrow Transplant. 9:1992;41.